Nicolas M. Van Mieghem

Nicolas M. Van Mieghem

Auto-generated profile, based on publicly available information

Nicolas M. Van Mieghem

Erasmus University Medical Center, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2019 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MBMarcelo Bastos
Marcelo Bastos
DBDaniel Burkhoff
Daniel Burkhoff
JMJiri Maly
Jiri Maly
JDJoost Daemen
Joost Daemen
CUCorstiaan Den Uil
Corstiaan Den Uil
NMNicolas M Van Mieghem
Nicolas M Van Mieghem
Ventricular pressure–volume (PV) analysis is the reference method for the study of cardiac mechanics. Advances in calibration algorithms and measuring techniques brought new perspectives for its application in different research and clinical settings. Simultaneous PV measurement in the heart chambers offers unique insights into mechanical cardiac efficiency. Beat to beat invasive PV monitoring can be instrumental in the understanding and management of heart failure, valvular heart disease, and mechanical cardiac support. This review focuses on intra cardiac left ventricular PV analysis principles, interpretation of signals, and potential clinical applications.

4 June 2013 in Circulation
Verified
Journal Article
Closed access
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
MSMarguerite E.I. Schipper
Marguerite E.I. Schipper
ELElena Ladich
Elena Ladich
EFElham Faqiri
Elham Faqiri
RBRobert van der Boon
Robert van der Boon
PJPeter P. de Jaegere
Peter P. de Jaegere
Background—: Recent transcatheter aortic valve replacement studies have raised concerns about adverse cerebrovascular events. The etiopathology of the embolized material is currently unknown. Methods and Results—: A total of 40 patients underwent transcatheter aortic valve replacement with the use of a dual filter–based embolic protection device (Montage Dual Filter System, Claret Medical, Inc). Macroscopic material liberated during the transcatheter aortic valve replacement procedure was captured in the device filter baskets in 30 (75%) patients and sent for histopathologic analysis. The captured material varied in size from 0.15 to 4.0 mm. Amorphous calcified material (size, 0.55–1.8 mm) was identified in 5 patients (17%). In 8 patients (27%), the captured material (size, 0.25–4.0 mm) contained valve tissue composed of loose connective tissue (collagen and elastic fibers) with focal areas of myxoid stroma, with or without coverage by endothelial cells and intermixed with fibrin. In another 13 (43%) patients, collagenous tissue, which may represent elements of vessel wall and valvelike structures, was identified. In 9 patients (30%), thrombotic material was intermixed with neutrophils (size, 0.15–2.0 mm). Overall, thrombotic material was found in 52% of patients, and tissue fragments compatible with aortic valve leaflet or aortic wall origin were found in 52% (21/40) of patients. Conclusions—: Embolic debris traveling to the brain was captured in 75% of transcatheter aortic valve replacement procedures where a filter-based embolic protection device was used. The debris consisted of fibrin, or amorphous calcium and connective tissue derived most likely from either the native aortic valve leaflets or aortic wall.

1 November 2012 in The American Journal of Cardiology
Verified
Journal Article
Closed access
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
DTDidier Tchetche
Didier Tchetche
ACAlaide Chieffo
Alaide Chieffo
NDNicolas Dumonteil
Nicolas Dumonteil
DMDavid Messika-Zeitoun
David Messika-Zeitoun
PJPeter P.T. de Jaegere
Peter P.T. de Jaegere

1 October 2022 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
GDG. Michael Deeb
G. Michael Deeb
LSLars Søndergaard
Lars Søndergaard
EGEberhard Grube
Eberhard Grube
SWStephan Windecker
Stephan Windecker
JYJames Yun
James Yun
Importance: In patients with severe aortic valve stenosis at intermediate surgical risk, transcatheter aortic valve replacement (TAVR) with a self-expanding supra-annular valve was noninferior to surgery for all-cause mortality or disabling stroke at 2 years. Comparisons of longer-term clinical and hemodynamic outcomes in these patients are limited. Objective: To report prespecified secondary 5-year outcomes from the Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI) randomized clinical trial. Design, Setting, and Participants: SURTAVI is a prospective randomized, unblinded clinical trial. Randomization was stratified by investigational site and need for revascularization determined by the local heart teams. Patients with severe aortic valve stenosis deemed to be at intermediate risk of 30-day surgical mortality were enrolled at 87 centers from June 19, 2012, to June 30, 2016, in Europe and North America. Analysis took place between August and October 2021. Intervention: Patients were randomized to TAVR with a self-expanding, supra-annular transcatheter or a surgical bioprosthesis. Main Outcomes and Measures: The prespecified secondary end points of death or disabling stroke and other adverse events and hemodynamic findings at 5 years. An independent clinical event committee adjudicated all serious adverse events and an independent echocardiographic core laboratory evaluated all echocardiograms at 5 years. Results: A total of 1660 individuals underwent an attempted TAVR (n = 864) or surgical (n = 796) procedure. The mean (SD) age was 79.8 (6.2) years, 724 (43.6%) were female, and the mean (SD) Society of Thoracic Surgery Predicted Risk of Mortality score was 4.5% (1.6%). At 5 years, the rates of death or disabling stroke were similar (TAVR, 31.3% vs surgery, 30.8%; hazard ratio, 1.02 [95% CI, 0.85-1.22]; P  =   .85). Transprosthetic gradients remained lower (mean [SD], 8.6 [5.5] mm Hg vs 11.2 [6.0] mm Hg; P < .001) and aortic valve areas were higher (mean [SD], 2.2 [0.7] cm 2 vs 1.8 [0.6] cm 2 ; P < .001) with TAVR vs surgery. More patients had moderate/severe paravalvular leak with TAVR than surgery (11 [3.0%] vs 2 [0.7%]; risk difference, 2.37% [95% CI, 0.17%- 4.85%]; P = .05). New pacemaker implantation rates were higher for TAVR than surgery at 5 years (289 [39.1%] vs 94 [15.1%]; hazard ratio, 3.30 [95% CI, 2.61-4.17]; log-rank P < .001), as were valve reintervention rates (27 [3.5%] vs 11 [1.9%]; hazard ratio, 2.21 [95% CI, 1.10-4.45]; log-rank P = .02), although between 2 and 5 years only 6 patients who underwent TAVR and 7 who underwent surgery required a reintervention. Conclusions and Relevance: Among intermediate-risk patients with symptomatic severe aortic stenosis, major clinical outcomes at 5 years were similar for TAVR and surgery. TAVR was associated with superior hemodynamic valve performance but also with more paravalvular leak and valve reinterventions.

5 March 2023 in The Lancet
Verified
Journal Article
Closed access
RDRoberto Diletti
Roberto Diletti
WDWijnand K Den Dekker
Wijnand K Den Dekker
JBJohan Bennett
Johan Bennett
CSCarl E Schotborgh
Carl E Schotborgh
RSRene van der Schaaf
Rene van der Schaaf
NMNicolas M Van Mieghem
Nicolas M Van Mieghem

1 April 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
NFNahid El Faquir
Nahid El Faquir
ZRZouhair Rahhab
Zouhair Rahhab
RRRamón Rodríguez-Olivares
Ramón Rodríguez-Olivares
JWJeroen Wilschut
Jeroen Wilschut
PJPeter P. de Jaegere
Peter P. de Jaegere